ProKidney Corp. (PROK)
| Market Cap | 499.91M -40.7% |
| Revenue (ttm) | 889,000 +190.5% |
| Net Income | -72.29M |
| EPS | -0.53 |
| Shares Out | 302.06M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 864,921 |
| Open | 1.630 |
| Previous Close | 1.640 |
| Day's Range | 1.625 - 1.680 |
| 52-Week Range | 1.450 - 3.480 |
| Beta | 1.72 |
| Analysts | Buy |
| Price Target | 6.25 (+277.64%) |
| Earnings Date | Aug 21, 2026 |
About PROK
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, a... [Read more]
Financial Performance
In 2025, ProKidney's revenue was $893,000, an increase of 1075.00% compared to the previous year's $76,000. Losses were -$68.99 million, 12.7% more than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for PROK stock is "Buy." The 12-month stock price target is $6.25, which is an increase of 277.64% from the latest price.
News
ProKidney Transcript: Jefferies Global Healthcare Conference 2026
Rilparencel, an autologous cell therapy for advanced CKD, is in phase III trials aiming to delay or prevent dialysis and improve patient outcomes. Key data readouts are expected in 2027 and 2029, with a large market opportunity and favorable safety profile supporting future commercialization.
ProKidney appoints Kenneth Locke as chief technical officer
ProKidney (PROK) announced the appointment of Kenneth Locke as chief technical officer. Locke joins ProKidney from Carisma Therapeutics (CARM), where he oversaw CMC, Quality and Regulatory functions a...
ProKidney Appoints Kenneth Locke as Chief Technical Officer
Kenneth Locke joins as Chief Technical Officer, bringing more than 25 years of experience across Chemistry, Manufacturing and Controls (CMC) and Supply Chain as ProKidney progresses toward the potenti...
ProKidney Transcript: AGM 2026
The meeting approved all director nominees and auditor ratification, confirmed strategic progress on rilparencel's clinical development, and outlined plans for Phase III completion in 2026 with a key data readout expected in Q2 2027.
ProKidney reports Q1 EPS (14c), consensus (14c)
Reports Q1 revenue $226,000, consensus $100,250.”As we progress through 2026, we continue to build on the momentum established last year through positive Phase 2 REGEN-007 results, alignment with the ...
ProKidney sees cash runway into mid-2027
The company said, “Cash, cash equivalents and marketable securities as of March 31, 2026, totaled $224.9 million, compared to $270.0 million as of December 31, 2025. We expect that our…
ProKidney Reports First Quarter 2026 Financial Results and Business Highlights
WINSTON-SALEM, N.C., May 15, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney diseas...
ProKidney Quarterly report: Q1 2026
ProKidney has published its Q1 2026 quarterly earnings report on May 15, 2026.
ProKidney Earnings release: Q1 2026
ProKidney released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
ProKidney Proxy statement: Proxy filing
ProKidney filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
ProKidney Proxy statement: Proxy filing
ProKidney filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
ProKidney appoints Greg Madison as chief commercial officer
ProKidney (PROK) announced the appointment of Greg Madison as chief commercial officer. In this role, Madison will drive ProKidney’s commercial strategy as the company advances towards the potential c...
ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer
WINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney dise...
ProKidney reports Q4 EPS (52c), consensus (15c)
Reports Q4 revenue $893,000, consensus $600,000. “2025 was a pivotal year for ProKidney (PROK), highlighted by positive Phase 2 REGEN-007 study results, alignment with the FDA on the accelerated appro...
ProKidney Earnings release: Q4 2025
ProKidney released its Q4 2025 earnings on March 18, 2026, summarizing the period's financial results.
ProKidney Annual report: Q4 2025
ProKidney has published its Q4 2025 annual report on March 18, 2026.
ProKidney Transcript: 44th Annual J.P. Morgan Healthcare Conference
Rilparencel, an autologous cell therapy, is advancing through a pivotal phase III trial for advanced CKD, with top-line data expected in Q2 2027. Phase II results showed significant improvement in kidney function and strong safety, while manufacturing and commercial preparations are underway.
ProKidney Slides: 44th Annual J.P. Morgan Healthcare Conference
ProKidney has posted slides in relation to its latest quarterly earnings report, which was published on January 14, 2026.
ProKidney Slides: Corporate presentation
ProKidney has posted slides in relation to its latest quarterly earnings report, which was published on January 12, 2026.
ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference
WINSTON-SALEM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disea...
ProKidney initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis initiated coverage of ProKidney (PROK) with a Buy rating and $12 price target The company is pioneering an approach to postponing progressive kidney dysfunctio...
ProKidney Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
The company is advancing an autologous cell therapy for advanced CKD, with phase III trials over 50% enrolled and an accelerated approval readout expected in Q2 2027. Strong phase II data, a robust safety profile, and significant market potential support commercial prospects.
ProKidney reports Q3 EPS (12c), consensus (14c)
Reports Q3 revenue $217,000, consensus $44,250. “The Phase 2 REGEN-007 full results recently presented at ASN Kidney Week further strengthen the body of evidence supporting our ongoing Phase 3 PROACT…
ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
WINSTON-SALEM, N.C., Nov. 10, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disea...
ProKidney Earnings release: Q3 2025
ProKidney released its Q3 2025 earnings on November 10, 2025, summarizing the period's financial results.